Compare Stocks: OPK, GOSS, and KPTI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GOSS Gossamer Bio	$0.18 -11.0%	$0.17	$0.11 ▼ $3.87	$42.72M	2.04	18.89 million shs	14.86 million shs
KPTI Karyopharm Therapeutics	$1.90 -1.3%	$6.46	$1.79 ▼ $10.99	$43.21M	0.89	973,174 shs	154,472 shs
OPK OPKO Health	$1.50 +0.3%	$1.38	$0.98 ▼ $1.73	$1.12B	1.51	2.99 million shs	1.68 million shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GOSS Gossamer Bio	+16.86%	+42.91%	+50.37%	-6.15%	-91.33%
KPTI Karyopharm Therapeutics	+3.23%	-0.52%	-74.09%	-78.62%	-69.57%
OPK OPKO Health	+0.68%	+9.56%	+22.13%	+14.62%	+7.19%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GOSS Gossamer Bio	$0.18 -11.0%	$0.17	$0.11 ▼ $3.87	$42.72M	2.04	18.89 million shs	14.86 million shs
KPTI Karyopharm Therapeutics	$1.90 -1.3%	$6.46	$1.79 ▼ $10.99	$43.21M	0.89	973,174 shs	154,472 shs
OPK OPKO Health	$1.50 +0.3%	$1.38	$0.98 ▼ $1.73	$1.12B	1.51	2.99 million shs	1.68 million shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GOSS Gossamer Bio	+16.86%	+42.91%	+50.37%	-6.15%	-91.33%
KPTI Karyopharm Therapeutics	+3.23%	-0.52%	-74.09%	-78.62%	-69.57%
OPK OPKO Health	+0.68%	+9.56%	+22.13%	+14.62%	+7.19%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GOSS Gossamer Bio	2.22	Hold	$3.20	1,658.24% Upside
KPTI Karyopharm Therapeutics	2.57	Moderate Buy	$11.50	506.86% Upside
OPK OPKO Health	2.00	Hold	$1.55	3.68% Upside

Current Analyst Ratings Breakdown

Latest OPK, GOSS, and KPTI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2026	GOSS Gossamer Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/13/2026	KPTI Karyopharm Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	OPK OPKO Health	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/31/2026	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Negative
7/31/2026	KPTI Karyopharm Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$7.00
7/31/2026	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$3.00
7/31/2026	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$13.00 ➝ $3.00
7/29/2026	OPK OPKO Health	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/28/2026	KPTI Karyopharm Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	GOSS Gossamer Bio	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$1.00
7/27/2026	GOSS Gossamer Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 8/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GOSS Gossamer Bio	$48.47M	0.88	N/A	N/A	($0.40) per share	-0.46
KPTI Karyopharm Therapeutics	$146.62M	0.29	N/A	N/A	($14.56) per share	-0.13
OPK OPKO Health	$587.90M	1.90	N/A	N/A	$1.59 per share	0.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GOSS Gossamer Bio	-$170.37M	-$0.70	N/A	N/A	N/A	-235.00%	N/A	-112.04%	11/4/2026 (Estimated)
KPTI Karyopharm Therapeutics	-$196.04M	-$13.09	N/A	N/A	N/A	-153.28%	N/A	-145.18%	11/2/2026 (Estimated)
OPK OPKO Health	-$225.68M	-$0.09	N/A	N/A	N/A	-12.40%	-5.88%	-3.83%	11/4/2026 (Estimated)

Latest OPK, GOSS, and KPTI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	GOSS Gossamer Bio	-$0.1234	-$0.08	+$0.0434	-$0.08	$3.63 million	$9.24 million
8/13/2026	Q2 2026	KPTI Karyopharm Therapeutics	-$1.37	-$2.32	-$0.95	-$2.32	$32.19 million	$33.43 million
7/27/2026	Q2 2026	OPK OPKO Health	-$0.08	-$0.01	+$0.07	-$0.01	$131.23 million	$163.58 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A
OPK OPKO Health	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GOSS Gossamer Bio	N/A	0.53	0.53
KPTI Karyopharm Therapeutics	N/A	0.79	0.76
OPK OPKO Health	0.28	3.35	2.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GOSS Gossamer Bio	81.23%
KPTI Karyopharm Therapeutics	66.44%
OPK OPKO Health	64.63%

Insider Ownership

Company	Insider Ownership
GOSS Gossamer Bio	3.74%
KPTI Karyopharm Therapeutics	1.68%
OPK OPKO Health	44.72%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GOSS Gossamer Bio	180	234.70 million	225.92 million	Optionable
KPTI Karyopharm Therapeutics	380	22.68 million	22.30 million	Optionable
OPK OPKO Health	1,373	746.33 million	412.57 million	Optionable

OPK, GOSS, and KPTI Headlines

Recent News About These Companies

AWM Investment Company Inc. Makes New Investment in OPKO Health, Inc. $OPK

August 26 at 3:22 AM | marketbeat.com

Here's Why You Should Retain OPK Stock in Your Portfolio for Now

August 24 at 2:36 PM | finance.yahoo.com

Here's Why You Should Retain OPK Stock in Your Portfolio for Now

August 24 at 12:16 PM | zacks.com

Zacks Research Increases Earnings Estimates for OPKO Health

August 21, 2026 | americanbankingnews.com

Opko’s CTAP101 Pediatric Trial: A New Angle on Kidney Care Growth

August 20, 2026 | tipranks.com

OPK Raises $125 Million Against Royalties: What Investors Should Know

August 19, 2026 | zacks.com

Is OPK Worth Buying as Valuation Meets Improving Business Trends?

August 19, 2026 | zacks.com

OPK Climbs 12.4% in the Past Month: Can the Stock Rally Keep Going?

August 19, 2026 | zacks.com

Zacks Research Has Positive View of OPKO Health Q3 Earnings

August 19, 2026 | marketbeat.com

OPKO Health, Inc. (NASDAQ:OPK) Receives $1.55 Consensus Price Target from Analysts

August 19, 2026 | americanbankingnews.com

OPKO Health Secures $125 Million Financing Against Mazdutide Royalties

August 18, 2026 | zacks.com

OPKO Health (NASDAQ:OPK) Stock Price Down 5.4% - Should You Sell?

August 16, 2026 | americanbankingnews.com

OPKO Health Issues Additional $125 Million in Senior Notes Secured by Mazdutide Royalties

August 14, 2026 | finance.yahoo.com

OPKO Health (NASDAQ:OPK) Trading Down 5.4% - Here's What Happened

August 14, 2026 | marketbeat.com

OPKO Health, Inc. (NASDAQ:OPK) Given Consensus Rating of "Hold" by Analysts

August 14, 2026 | marketbeat.com

OPKO Health, Inc.: OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests

August 13, 2026 | finanznachrichten.de

OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests

August 13, 2026 | finance.yahoo.com

OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests

August 13, 2026 | globenewswire.com

OPKO Health: Mazdutide And MDX-2201 Could Change Everything

August 4, 2026 | seekingalpha.com

OPKO Health (OPK) Upgraded to Buy: Here's What You Should Know

August 4, 2026 | finance.yahoo.com

OPKO Health (OPK) Upgraded to Buy: Here's What You Should Know

August 4, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OPK, GOSS, and KPTI Company Descriptions

Gossamer Bio NASDAQ:GOSS

$0.18 -0.02 (-11.00%)

As of 12:23 PM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Karyopharm Therapeutics NASDAQ:KPTI

$1.90 -0.03 (-1.30%)

As of 12:23 PM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

OPKO Health NASDAQ:OPK

$1.50 +0.01 (+0.34%)

As of 12:23 PM Eastern

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OPK, GOSS, and KPTI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OPK, GOSS, and KPTI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OPK, GOSS, and KPTI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

OPK, GOSS, and KPTI Company Descriptions

Gossamer Bio NASDAQ:GOSS

Karyopharm Therapeutics NASDAQ:KPTI

OPKO Health NASDAQ:OPK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OPK, GOSS, and KPTI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OPK, GOSS, and KPTI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OPK, GOSS, and KPTI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

OPK, GOSS, and KPTI Company Descriptions

Gossamer Bio NASDAQ:GOSS

Karyopharm Therapeutics NASDAQ:KPTI

OPKO Health NASDAQ:OPK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools